New ventilation strategy aims to reduce lung damage in severe pneumonia

NCT ID NCT07679802

Disease control Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a new way of using a breathing machine (ventilator) called time-controlled adaptive ventilation (TCAV) in people with severe lung injury from pneumonia. The goal is to see if TCAV reduces fluid buildup in the lungs compared to standard ventilation. The trial involves 56 adults in the intensive care unit who need a breathing machine. If TCAV works, it could lead to better outcomes and fewer complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: Time-controlled adaptive ventilation (TCAV) using Airway Pressure Release Ventilation mode
What this could lead to: If effective, TCAV could offer a simple, low-cost way to reduce lung injury and improve survival in patients with severe respiratory failure.
What could go wrong: This is a small pilot study with 56 participants, so results may not apply broadly. The new ventilation method could also cause harm, such as worsening oxygen levels or kidney problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 56 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2026

An estimate. Start dates often move.

Expected to finish

Nov 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Intensive care unit hospitalisation for ARDS with a PaO₂/FiO₂ ratio ≤ 200 mmHg and PEEP ≥ 5 cmH₂O under invasive ventilation * Criteria for community-acquired pneumonia, 2 of the following: cough, purulent sputum, chest pain, dyspnea * Onset of symptoms ≤ 7 days * Invasive ventilation initiated ≤ 24 hours * Affiliation to a social security program * Patient for whom written consent has been obtained from a trusted person or a family member, or inclusion in a situation of immediate life-threatening emergency Exclusion Criteria: * Focal ARDS defined as unilateral involvement (1 out of 4 quadrants or 2 on the same side) on imaging (chest X-ray or CT scan) * Right heart failure not related to acute pulmonary heart disease secondary to ARDS (pulmonary embolism, myocarditis, ischemic cause) * Pneumothorax, drained or undrained, with a persistent pleural air leak * COPD with significant obstructive impairment defined by the presence of chronic respiratory disease and oxygen therapy or non-invasive ventilation at home * Circulatory support via VV-ECMO or VA-ECMO * Presence of a patent foramen ovale * Active limitation of therapies * Increased intracranial pressure * Sickle cell disease * Burns \> 30% * Expected invasive mechanical ventilation for less than 48 hours * A person covered by Articles L. 1121-5, L. 1121-7, and L. 1121-8 of the French Public Health Code * Pregnant or breastfeeding women * A not emancipated minor * Adults subject to legal protective measures (guardianship, conservatorship, judicial protection) or inability to give consent * Persons deprived of liberty by a judicial or administrative decision, persons receiving psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ARDS (acute respiratory distress syndrome) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute lung injury acute respiratory distress syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ARDS (acute respiratory distress syndrome)

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

1 site. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

New ventilation strategy aims to reduce lung damage in severe pneumonia

What the study statuses mean